Value proposition

SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
sitc_log_color.png

Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.

Currently, SITC has more than 2,000 members who represent 22 medical specialties in 42 countries around the world.

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.

SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

Cancer, Oncology, Immunotherapy, Networking, T Cells, Vaccines, Cytokines, Monoclonal Antibodies, Clinical Trials, Biomarkers, Personalized Medicine, Cancer Stem Cells, Phase I, Phase II, Phase III, Human Immunology, Tumor Microenvironment, and Targeted Therapeutics